Lexaria Bioscience Corp. announced on February 6, 2025, that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide (FTS) rodent biodistribution study. This study is designed to track how DehydraTECH-processed GLP-1 molecules distribute within the body.
The study aims to discover whether DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to conventional orally administered semaglutide. Fluorescent imaging detection will be used to track FTS following oral ingestion by Sprague-Dawley rats.
Later in the study, various key tissues, including the brain, pancreas, lung, kidney, liver, and heart, will be examined for specific tissue localization patterns and concentrations. Results from this study will enhance future communications with prospective industry partners.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.